nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
1 |
Collateral damage and the criminalisation of drug use
|
Maher, Lisa |
|
2017 |
4 |
8 |
p. e326-e327 nvt p. |
artikel |
2 |
HIV and the criminalisation of drug use among people who inject drugs: a systematic review
|
DeBeck, Kora |
|
2017 |
4 |
8 |
p. e357-e374 nvt p. |
artikel |
3 |
Improved life expectancy of people living with HIV: who is left behind?
|
Katz, Ingrid T |
|
2017 |
4 |
8 |
p. e324-e326 nvt p. |
artikel |
4 |
Initiatives to fill the gaps in Africa's AIDS response
|
The Lancet HIV, |
|
2017 |
4 |
8 |
p. e321- 1 p. |
artikel |
5 |
Long-acting cabotegravir for prevention: hope versus reality
|
McCormack, Sheena |
|
2017 |
4 |
8 |
p. e322-e323 nvt p. |
artikel |
6 |
Methodological and statistical issues related to analysis of survival
|
Alizadeh, Ahad |
|
2017 |
4 |
8 |
p. e330- 1 p. |
artikel |
7 |
Methodological and statistical issues related to analysis of survival – Authors' reply
|
Trickey, Adam |
|
2017 |
4 |
8 |
p. e330- 1 p. |
artikel |
8 |
Nucleoside reverse-transcriptase inhibitor cross-resistance and outcomes from second-line antiretroviral therapy in the public health approach: an observational analysis within the randomised, open-label, EARNEST trial
|
Paton, Nicholas I |
|
2017 |
4 |
8 |
p. e341-e348 nvt p. |
artikel |
9 |
Resistance matters in EARNEST
|
Maartens, Gary |
|
2017 |
4 |
8 |
p. e323-e324 nvt p. |
artikel |
10 |
Safety and tolerability of long-acting cabotegravir injections in HIV-uninfected men (ECLAIR): a multicentre, double-blind, randomised, placebo-controlled, phase 2a trial
|
Markowitz, Martin |
|
2017 |
4 |
8 |
p. e331-e340 nvt p. |
artikel |
11 |
Survival of HIV-positive patients starting antiretroviral therapy between 1996 and 2013: a collaborative analysis of cohort studies
|
|
|
2017 |
4 |
8 |
p. e349-e356 nvt p. |
artikel |
12 |
The effect of treatment simplification on HIV reservoirs
|
Darcis, Gilles |
|
2017 |
4 |
8 |
p. e328-e329 nvt p. |
artikel |